Recombinant antithrombin: Production and role in cardiovascular disorder

Seminars in Thrombosis and Hemostasis

Volumn 27, Issue 4, 2001, Pages 405-416

  Levy, J H ^a   Weisinger, A ^a   Ziomek, C A ^a   Echelard, Y ^a  

^a EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

Cardiopulmonary bypass; Clinical trials; Heparin resistance; Recombinant antithrombin; Transgenic production

Indexed keywords

ANTITHROMBIN; FRESH FROZEN PLASMA; HEPARIN; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; CARDIOPULMONARY BYPASS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DOSE RESPONSE; EXTRACORPOREAL CIRCULATION; FRACTIONATION; GOAT; HUMAN; HYPERCOAGULABILITY; ISCHEMIC HEART DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PURIFICATION; REVIEW; TRANSGENIC ANIMAL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTITHROMBINS; CARDIOVASCULAR DISEASES; GOATS; HUMANS; MILK; RECOMBINANT PROTEINS;

EID: 0034868433     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-16893     Document Type: Review

References (123)

1. Binding of thrombin to antithrombin III
2. Identity of plasma-activated factor X inhibitor with antithrombin 3 and heparin cofactor
3. The purification and mechanism of action of human antithrombin-heparin cofactor
4. Inhibition of human factor IXa by human antithrombin-heparin cofactor
5. Inhibition of bovine factor IXa and factor Xa by antithrombin III
6. Inhibition of activated factor XII by antithrombin-heparin cofactor
7. Regulation of factor VIIa activity in plasma: Evidence that antithrombin III is the sole plasma protease inhibitor of human factor VIIa
8. Molecular basis of an inherited human antithrombin deficiency
9. Crossed immunoelectrophoresis applied to studies on complex formation. The binding of heparin to antithrombin III and the antithrombin-thrombin complex
10. Identification of a serpin-enzyme complex receptor on human hepatoma cells and human monocytes
11. Serpin receptor 1: A hepatic receptor that mediates the clearance of antithrombin III-proteinase complexes
12. Inherited antithrombin deficiency causing thrombophilia
13. Antithrombin III deficiency and thromboembolism
14. Congenital antithrombin III deficiency
15. Antithrombin III concentrates - Are they clinically useful?
16. Antithrombin and its inherited states
17. Acquired antithrombin III deficiency: Laboratory diagnosis, incidence, clinical implications, and treatment with antithrombin III concentrate
18. Clinical relevance of antithrombin deficiencies
19. Treatment of hereditary and acquired thrombophilic disorders
20. Studies of components of the coagulation systems in normal individuals and septic shock patients
21. Sepsis and antithrombin III, prekallikrein, and fibronectin levels in surgical patients
22. Septic shock, multiple organ failure, and disseminated intravascular coagulation, Compared patterns of antithrombin III, protein C, and protein S deficiencies
23. Antithrombin levels related to infections and outcome
24. Effect of critical injury on plasma antithrombin activity: Low antithrombin levels are associated with thromboembolic complications
25. Substitution therapy with an antithrombin III concentrate in shock and DIC
26. Therapeutic use of antithrombin III in shock and disseminated intravascular coagulation
27. Evaluation of the safety, recovery, half-life, and clinical efficacy of antithrombin III (human) in patients with hereditary antithrombin III deficiency
28. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation
29. Antithrombin III in hematopoietic stem cell transplantation
30. Therapeutic use of antithrombin concentrate in sepsis
31. Uses of antithrombin III concentrate in congenital and acquired deficiency states
32. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis
33. The treatment of heparin resistance with antithrombin III in cardiac surgery
34. Efficacy of antithrombin replacement therapy in severe early-onset pre-eclampsia
35. Hereditary and acquired antithrombin deficiency
36. A randomized trial of antithrombin concentrate for treatment of heparin resistance
37. The production of pharmaceutical proteins from the milk of transgenic animals
38. Recombinant protein production in transgenic animals
39. Expression of recombinant proteins in the milk of transgenic animals
40. The mammary gland as a bioreactor: Expression, processing, and production of recombinant proteins
41. Induction of human tissue plasminogen activator in the mammary gland of transgenic goats
42. Transgenically produced human antithrombin: Structural and functional comparison to human plasma-derived antithrombin
43. Transgenic milk as a method for the production of recombinant antibodies
44. Cloning of the goat beta-casein-encoding gene and expression in transgenic mice
45. Influence of glycosylation on the functional properties of human therapeutic plasma proteins
46. Effect of individual carbohydrate chains of recombinant antithrombin on heparin affinity
47. Antithrombin-heparin affinity reduced by fucosylation of carbohydrate at asparagine 155
48. Recombinant human antithrombin III improves s survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli
49. Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons
50. Antithrombin III stimulates prostacyclin production by cultured aortic endothelial cells
51. Heparin-like glycosaminoglycan is a receptor for antithrombin III-dependent but not for thrombin-dependent prostacyclin production in human endothelial cells
52. Effects of antithrombin III (AT III) and Trp49-modified AT III on plasma level of 6-keto-PGF1 alpha in rats
53. Attenuation of endotoxin-induced pulmonary vascular injury by antithrombin III
54. Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion
55. Effects of a combined antithrombin III and protein C supplementation in porcine acute endotoxic shock
56. Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis
57. Influence of antithrombin III on coagulation and inflammation in porcine septic shock
58. Antithrombin reduces leukocyte adhesion during chronic endotoxemia by modulation of the cyclooxygenase pathway
59. The anti-inflammatory properties of antithrombin III: New therapeutic implications
60. Antithrombin III in animal models of sepsis and organ failure
61. Antithrombin III reduces mesenteric venule leukocyte adhesion and small intestine injury in endotoxemic rats
62. The hemostatic mechanism after open heart surgery: I. Studies on plasma coagulation factors and fibrinolysis in 512 patients after extracorporeal circulation
63. Surface mediated defense reactions. The plasma contact activation system
64. Role of the contact system in fibrinolysis
65. Bleeding complications associated with cardiopulmonary bypass
66. Molecular and cellular biology of blood coagulation
67. Waterfall sequence for intrinsic blood clotting
68. The plasminogen activator/plasmin system
69. Studies on a complex mechanism for the activation of plasminogen by kaolin and chloroform: The participation of Hageman factor and additional cofactors
70. Thrombin stimulates tissue plasminogen activator release from cultured human endothelial cells
71. Studies on the kinetics of plasminogen activation by tissue plasminogen activator
72. The clinical significance of fibrinogen degradation products
73. The coagulation system and cardiac surgery
74. Plasma-heparin concentration in extracorporeal circulation
75. Clinical experience with the activated clotting time for the control of heparin and protamine therapy during cardiopulmonary bypass
76. Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass
77. The role of the activated clotting time in heparin administration and neutralization for cardiopulmonary bypass
78. Heparin dosing and monitoring for cardiopulmonary bypass
79. Response to heparinization in adults and children undergoing cardiac operations
80. Activated coagulation time of whole blood
81. Heparin therapy during extracorporeal circulation. I. Problems in existing heparin protocols
82. Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage
83. Monitoring of intraoperative heparinization and blood loss following cardiopulmonary bypass surgery
84. Heparin reversal of protamine toxicity: Have we come full circle?
85. Management of postop heparin rebound following cardiopulmonary bypass
86. Control of heparinization by activated clotting time during bypass with improved postoperative hemostasis
87. A simple method of heparin management during prolonged extracorporeal circulation
88. Low activated clotting time does not increase postoperative bleeding
89. Thrombin generation during cardiac surgery: Is heparin the ideal anticoagulant?
90. Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers
91. Mechanisms of thrombin generation during surgery and cardiopulmonary bypass
92. SPI Research Group: Postoperative myocardial ischemia in patients undergoing coronary bypass graft surgery
93. Predictive value of in vitro and in vivo studies for correct individual heparinization in cardiac surgery
94. Results of a survey of the professional activities of 811 cardiopulmonary perfusionists
95. Heparin anticoagulation during cardiac surgery in an AT-III deficient patient
96. Excessive requirement for heparin during cardiac surgery
97. Increased heparin requirement with hypereosinophilic syndrome
98. Identification of heparin resistance during cardiac and vascular surgery
99. Heparin resistance after preoperative heparin therapy or intraaortic balloon pumping
100. The influence of preoperative anticoagulation on heparin response during cardiopulmonary bypass
101. Diminished anticoagulant response to heparin in patients undergoing coronary bypass grafting
102. Heparin-induced decrease in circulating antithrombin-III
103. Prevention of heparin-induced thrombocytopenia during open heart surgery with iloprost (ZK 36374)
104. Heparin induced platelet activation in sixteen surgical patients: Diagnosis and management
105. AT III in patients treated with subcutaneous or intravenous heparin
106. Fresh frozen plasma: A solution to heparin resistance during cardiopulmonary bypass
107. In vitro effect of fresh frozen plasma on the activated coagulation time in patients undergoing cardiopulmonary bypass
108. Effect of antithrombin III substitution on heparin response during extracorporeal circulation
109. Heparin and antithrombin III levels during cardiopulmonary bypass correlation with subclinical plasma coagulation
110. Rate of protamine administration: Its effect on heparin reversal and antithrombin recovery after coronary artery surgery
111. The in vitro effects of antithrombin III on the activated coagulation time in patients on heparin therapy
112. Antithrombin III during cardiac surgery: Effect on response of activated clotting time to heparin and relationship to markers of hemostatic activation
113. Advances in antithrombotic drug therapy for coronary artery disease
114. Alteration of plasma antithrombin III levels in ischemic heart disease
115. Natural coagulation inhibitors: An assessment in patients
116. Coagulation, fibrinolytic, and inhibitory proteins in acute myocardial infarction and angina pectoris
117. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes
118. Antithrombin III plasma activity during and after prolonged use of heparin in unstable angina
119. Temporal relation between ischemic episodes and activation of the coagulation system in unstable angina
120. Persistent thrombin generation during heparin therapy in patients with acute coronary syndromes
121. Antithrombin III supplementation for patients undergoing PTCA for unstable angina pectoris. A controlled randomized double-blind pilot study
122. Pharmacokinetics of recombinant transgenic antithrombin in volunteers
123. Transgenically produced recombinant human ATIII enhances the antithrombotic effects of heparin in patients undergoing surgery